Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Chlorpheniramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 0.81 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.84 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.84 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.84 |
| ▸ | RAB9A | P51151 | 1/20 | 0.84 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.81 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.81 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.81 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.81 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.81 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.81 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.81 |
| ▸ | HTR2A | P28223 | 3/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorpheniramine SCHEMBL14973510 | 1.00 | LMNA (1.00) | LMNAPMP22BLMNPSR1TSHR | |
| Chlorpheniramine SCHEMBL30487016 | 1.00 | LMNA (1.00) | LMNAPMP22BLMNPSR1TSHR | |
| Dexchlorpheniramine SCHEMBL119500 | 1.00 | LMNA (1.00) | LMNAPMP22BLMNPSR1TSHR | |
| Chlorpheniramine SCHEMBL27719385 | 1.00 | LMNA (1.00) | LMNAPMP22BLMNPSR1TSHR | |
| Chlorpheniramine SCHEMBL33358 | 1.00 | LMNA (1.00) | LMNAPMP22BLMNPSR1TSHR | |
| Chlorpheniramine SCHEMBL33357 | 1.00 | LMNA (1.00) | LMNAPMP22BLMNPSR1TSHR | |
| Chlorpheniramine SCHEMBL4284232 | 0.99 | LMNA (0.98) | LMNAPMP22BLMNPSR1TSHR | |
| Chlorpheniramine SCHEMBL4284230 | 0.99 | LMNA (0.98) | LMNAPMP22BLMNPSR1TSHR | |
| Chlorpheniramine SCHEMBL28130816 | 0.99 | LMNA (0.98) | LMNAPMP22BLMNPSR1TSHR | |
| Chlorpheniramine SCHEMBL10002622 | 0.99 | LMNA (0.98) | LMNAPMP22BLMNPSR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111138350-B | Asymmetric synthesis method of dexchlorpheniramine and dexbrompheniramine | 中国药科大学 | 2021-08-10 | — | — | CN | disclosed |
| CN-111138350-A | Asymmetric synthesis method of dexchlorpheniramine and dexbrompheniramine | 中国药科大学 | 2020-05-12 | — | — | CN | disclosed |
| US-20090280153-A1 | electrical devices, anti-scarring agents, and therapeutic compositions | ANGIOTECH INTERNATIONAL AG (CH) | 2009-11-12 | — | — | US | disclosed |
| US-20090226500-A1 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC (CA) | 2009-09-10 | — | — | US | disclosed |
| EP-1978930-A2 | SUTURES AND ANTI-SCARRING AGENTS | Angiotech Pharmaceuticals, Inc. (CA) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007089878-A2 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2007-08-09 | — | — | WO | disclosed |
| WO-2006121522-A2 | IMPLANTABLE SENSORS AND PUMPS, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121518-A2 | ELECTRICAL DEVICES, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226500-A1 | SUTURES AND ANTI-SCARRING AGENTS | COL1A1, COL2A1, COL14A1 | HRH1 1421/4885LMNA 844/4885PMP22 1426/4885 |
| US-20090280153-A1 | electrical devices, anti-scarring agents, and therapeutic compositions | GAP43, TNNC1, GJB2 | HRH1 2230/4885LMNA 1322/4885PMP22 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.